Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1984 Jul;45(1):25–28. doi: 10.1128/iai.45.1.25-28.1984

In vivo and in vitro administration of interleukin 2-containing preparation reverses T-cell unresponsiveness in Mycobacterium bovis BCG-infected mice.

V Colizzi
PMCID: PMC263252  PMID: 6376356

Abstract

Mice infected with high doses of Mycobacterium bovis BCG (3 X 10(7)) showed a marked impairment of delayed-type hypersensitivity to PPD in vivo, and their splenic T cells failed to proliferate when cultured in vitro with concanavalin A or PPD. However, this state of unresponsiveness could be reversed both in vitro and in vivo by the administration of an interleukin 2 (IL-2)-containing preparation. IL-2 produced spontaneously by the gibbon lymphosarcoma T-cell line MLA-144 and T-cell-conditioned medium from a mixed lymphocyte reaction were able to increase DNA synthesis of splenic T lymphocytes from BCG-immunosuppressed mice cultured with concanavalin A or PPD. Furthermore, BCG-infected mice treated in vivo with at least 100 U of IL-2 showed a positive skin reaction to PPD, and their spleen cells were fully responsive in vitro. The reversal of BCG-induced immunosuppression was not observed when infected mice were injected with IL-2 preparations previously incubated with blast cells, a procedure known to remove IL-2 activity. These results indicate that the basis of BCG-induced unresponsiveness is a deficiency in the production of IL-2 rather than a lack of reactive T cells.

Full text

PDF
25

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bjune G., Closs O., Barnetson R. S. Early events in the host-parasite relationship and immune response in clinical leprosy: its possible importance for leprosy control. Clin Exp Immunol. 1983 Nov;54(2):289–297. [PMC free article] [PubMed] [Google Scholar]
  2. Bullock W. E. Anergy and infection. Adv Intern Med. 1976;21:149–173. [PubMed] [Google Scholar]
  3. Cheever M. A., Greenberg P. D., Fefer A., Gillis S. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med. 1982 Apr 1;155(4):968–980. doi: 10.1084/jem.155.4.968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Colizzi V., Ferluga J., Garreau F., Malkovsky M., Asherson G. L. Suppressor cells induced by BCG release non-specific factors in vitro which inhibit DNA synthesis and interleukin-2 production. Immunology. 1984 Jan;51(1):65–71. [PMC free article] [PubMed] [Google Scholar]
  5. Colizzi V., Garzelli C., Campa M., Toca L., Falcone G. Role of specific delayed-type hypersensitivity in Pseudomonas aeruginosa-infected mice. Immunology. 1982 Oct;47(2):337–344. [PMC free article] [PubMed] [Google Scholar]
  6. Colizzi V., Giuntini M., Garzelli C., Campa M., Falcone G. Auto-anti-idiotypic antibodies inhibit T-cell-mediated hypersensitivity in BCG-infected mice. Cell Immunol. 1983 Aug;80(1):205–210. doi: 10.1016/0008-8749(83)90107-7. [DOI] [PubMed] [Google Scholar]
  7. Collins F. M., Morrison N. E., Montalbine V. Immune response to persistent mycobacterial infection in mice. Infect Immun. 1978 May;20(2):430–438. doi: 10.1128/iai.20.2.430-438.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Collins F. M., Watson S. R. Suppressor T-cells in BCG-infected mice. Infect Immun. 1979 Aug;25(2):491–496. doi: 10.1128/iai.25.2.491-496.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Donohue J. H., Rosenberg S. A. The fate of interleukin-2 after in vivo administration. J Immunol. 1983 May;130(5):2203–2208. [PubMed] [Google Scholar]
  10. Flomenberg N., Welte K., Mertelsmann R., Kernan N., Ciobanu N., Venuta S., Feldman S., Kruger G., Kirkpatrick D., Dupont B. Immunologic effects of interleukin 2 in primary immunodeficiency diseases. J Immunol. 1983 Jun;130(6):2644–2650. [PubMed] [Google Scholar]
  11. Granelli-Piperno A., Vassalli J. D., Reich E. Purification of murine T cell growth factor. A lymphocyte mitogen with helper activity. J Exp Med. 1981 Aug 1;154(2):422–431. doi: 10.1084/jem.154.2.422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Haregewoin A., Godal T., Mustafa A. S., Belehu A., Yemaneberhan T. T-cell conditioned media reverse T-cell unresponsiveness in lepromatous leprosy. Nature. 1983 May 26;303(5915):342–344. doi: 10.1038/303342a0. [DOI] [PubMed] [Google Scholar]
  13. Hefeneider S. H., Conlon P. J., Henney C. S., Gillis S. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J Immunol. 1983 Jan;130(1):222–227. [PubMed] [Google Scholar]
  14. Hoffenbach A., Lagrange P. H., Bach M. A. Deficit of interleukin 2 production associated with impaired T-cell proliferative responses in Mycobacterium lepraemurium infection. Infect Immun. 1983 Jan;39(1):109–116. doi: 10.1128/iai.39.1.109-116.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lamoureux G., Poisson R. Letter: B.C.G. and immunological anergy. Lancet. 1974 May 18;1(7864):989–990. doi: 10.1016/s0140-6736(74)91296-3. [DOI] [PubMed] [Google Scholar]
  16. Malkovsky M., Asherson G. L., Stockinger B., Watkins M. C. Nonspecific inhibitor released by T acceptor cells reduces the production of interleukin-2. Nature. 1982 Dec 16;300(5893):652–655. doi: 10.1038/300652a0. [DOI] [PubMed] [Google Scholar]
  17. Malkovský M., Asherson G. L., Chandler P., Colizzi V., Watkins M. C., Zembala M. Nonspecific inhibitor of DNA synthesis elaborated by T acceptor cells. I. Specific hapten- and I-J-driven liberation of an inhibitor of cell proliferation by Lyt-1-2+ cyclophosphamide-sensitive T acceptor cells armed with a product of Lyt-1+2+-specific suppressor cells. J Immunol. 1983 Feb;130(2):785–790. [PubMed] [Google Scholar]
  18. Malkovský M., Medawar P., Hunt R., Palmer L., Doré C. A diet enriched in vitamin A acetate or in vivo administration of interleukin-2 can counteract a tolerogenic stimulus. Proc R Soc Lond B Biol Sci. 1984 Feb 22;220(1221):439–445. doi: 10.1098/rspb.1984.0012. [DOI] [PubMed] [Google Scholar]
  19. Marx J. L. Chemical signals in the immune system. Science. 1983 Sep 30;221(4618):1362–1364. doi: 10.1126/science.6604316. [DOI] [PubMed] [Google Scholar]
  20. Nakamura R. M., Tokunaga T. Induction of suppressor T cells in delayed-type hypersensitivity to Mycobacterium bovis BCG in low-responder mice. Infect Immun. 1980 May;28(2):331–335. doi: 10.1128/iai.28.2.331-335.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rabin H., Hopkins R. F., 3rd, Ruscetti F. W., Neubauer R. H., Brown R. L., Kawakami T. G. Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells. J Immunol. 1981 Nov;127(5):1852–1856. [PubMed] [Google Scholar]
  22. Turcotte R. Evidence for two distinct populations of suppressor cells in the spleens of Mycobacterium bovis BCG-Sensitized mice. Infect Immun. 1981 Nov;34(2):315–322. doi: 10.1128/iai.34.2.315-322.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Turcotte R., Lemieux S. Mechanisms of action of Mycobacterium bovis BCG-induced suppressor cells in mitogen-induced blastogenesis. Infect Immun. 1982 Apr;36(1):263–270. doi: 10.1128/iai.36.1.263-270.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wagner H., Hardt C., Heeg K., Röllinghoff M., Pfizenmaier K. T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice. Nature. 1980 Mar 20;284(5753):278–278. doi: 10.1038/284278a0. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES